{
  "study_id": "NCT05351541",
  "agent": "framework",
  "run": 5,
  "p_primary_hypothesis_supported": 0.84,
  "effect_direction": "favours intervention",
  "effect_size_90pct_interval": {"low": 3, "high": 20, "metric": "Mean change in BPI interference, 0-70 scale, baseline to 1 month (positive = reduction)"},
  "moderator_prediction": "Modafinil-containing arms (without zolpidem) reduce interference more and zolpidem arms less: mana value scales with attention, so a sedative that blunts attention and memory of the session books a shallower write, while a wakefulness agent keeps the saturated hour attended and recalled.",
  "claim_ids_used": ["PM-0090", "PM-0092", "PM-0110", "PM-0401", "PM-0485", "PM-1286", "PM-0159", "PM-0138", "PM-0361", "PM-0126", "PM-0457"],
  "rationale": "Every participant gets psilocybin with preparation and integration from trusted clinicians: a chemical backdoor that relaxes high-level priors plus authority and setting, two doors at once, in a charged single session. Pain interference is a felt, self-rated render-layer outcome, where belief acts most directly, and the Prover reads ambiguous bodily signals as improvement once 'I am getting better' is installed; unblinded-to-drug expectancy adds a confirming entry. With no untreated control, pre-post change also absorbs regression to the mean in treatment-refractory recruits. At 1 month recency still favours the impact-driven effect. n~30 gives adequate power for a within-subject change; main risk is dropout, sub-therapeutic doses, or reporting only between-arm contrasts."
}